Effect of intraoperative dexmedetomidine on renal function in patients undergoing cardiopulmonary bypass graft surgery under cardiopulmonary bypass

IntroductionThis study is aimed to evaluate the effect of intraoperative dexmedetomidine on renal function in patients undergoing cardiopulmonary bypass graft surgery (CABG)by using cardiopulmonary bypass (CBP).MethodsThis randomized clinical trial study was performed on 58 patients who were candidates for CABG. In the dexmedetomidine group, dexmedetomidine infusion at a dose of 0.5 μg / kg / h without a loading dose and in the control group placebo was initiated. After the end of surgery and ICU admission and on days 2 and 3 postoperatively, serum BUN, Cr, and eGFR levels, also urine output, Inotrope usage, and PRBC consumption were recorded. ResultNo significant differences were observed in any of the steps in serum creatinine levels between the two groups (P>0.05). A significant difference in serum BUN levels was observed between the two groups except for the third day (P0.05). There was a significant difference between the mean urine output in the two groups only on the second day (P=0.04). There was no significant difference in PRBC intake and inotrope usage between the two groups (P>0.05).ConclusionThe findings indicate that dexmedetomidine does not affect the renal function of patients undergoing coronary artery bypass graft surgery. According to the findings, dexmedetomidine can increase the urine output of patients during surgery. However, it has no positive effect on the postoperative period.